Mitochondrial Dysfunction in Cell Injury and Cardiotoxicity

Cardiotoxicity of Non-Cardiovascular Drugs

Volumn , Issue , 2010, Pages 1-23

  Di Lisa, Fabio ^a   Semenzato, Martina ^a   Carpi, Andrea ^a   Menazza, Sara ^a   Kaludercic, Nina ^a   Menabò, Roberta ^a   Canton, Marcella ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Ischemia induced ETC inhibition direct consequences; Mitochondria centered mechanisms cell injury; Mitochondrial dysfunction cell injury and cardiotoxicity; Myocardial function and oxygen supply mitochondrial substrate degradation; Myocardial ischemia mitochondrial relevance in cardiomyocyte injury; Pharmacological preconditioning IPC protection

Indexed keywords

EID: 84884271177     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470660379.ch1     Document Type: Chapter

References (121)

1. K.B. Wallace, E. Hausner, E. Herman, et al. Serum troponins as biomarkers of druginduced cardiac toxicity, Toxicol. Pathol., 32, 106-121 (2004).
2. K. B. Wallace, and A. A. Starkov, Mitochondrial targets of drug toxicity, Annu. Rev. Pharmacol. Toxicol. , 40, 353-388 (2000).
3. K. B. Wallace, Mitochondrial off targets of drug therapy, Trends Pharmacol. Sci. , 29, 361-366 (2008).
4. V. A. Sardao, S. L. Pereira, and P. J. Oliveira, Drug-induced mitochondrial dysfunction in cardiac and skeletal muscle injury, Expert. Opin. Drug Saf, 7, 129-146 (2008).
5. P. Bernardi, A. Krauskopf, E. Basso, et al. , The mitochondrial permeability transition from in vitro artifact to disease target, FEBS J. , 273, 2077-2099 (2006).
6. W. Rouslin, J. L. Erickson, R. J. Solaro, Effects of oligomycin and acidosis on rates of ATP depletion in ischemic heart muscle, Am. J. Physiol. , 250, H503-508 (1986).
7. F. Di Lisa, P. S. Blank, R. Colonna, et al. Mitochondrial membrane potential in single living adult rat cardiac myocytes exposed to anoxia or metabolic inhibition, J. Physiol. , 486, 1-13 (1995).
8. F. Di Lisa, P. Bernardi, Mitochondrial function as a determinant of recovery or death in cell response to injury, Mol. Cell Biochem. , 184, 379-391 (1998).
9. E. Murphy, C. Steenbergen, Preconditioning: The Mitochondrial Connection, Annu. Rev. Physiol, 69, 51-57 (2007).
10. R. B. Jennings, C. Steenbergen, Nucleotide metabolism and cellular damage in myocardial ischemia, Annu. Rev. Physiol. , 47, 727-749 (1985).
11. D. G. Allen, C. H. Orchard, Myocardial contractile function during ischemia and hypoxia, Circ. Res. , 60, 153-168 (1987).
12. J. A. Idell Wenger, L. W. Grotyohann, J. R. Neely, Coenzyme A and carnitine distribution in normal and ischemic hearts, J. Biol. Chem. , 253(12), 4310-8 (1978).
13. A. M. Katz, F. C. Messineo, Lipid-membrane interactions and the pathogenesis of ischemic damage in the myocardium, Circ. Res. , 48, 1-16 (1981).
14. P. B. Corr, R. W. Gross, B. E. Sobel, Amphipathic metabolites and membrane dysfunction in ischemic myocardium, Circ. Res. , 55, 135-154 (1984).
15. T. E. Gunter, D. R. Pfeiffer, Mechanisms by which mitochondria transport calcium, Am. J. Physiol. , 258, C755-786 (1990).
16. P. Bernardi, Mitochondrial transport of cations: channels, exchangers, permeability transition, Physiol. Rev. , 79, 1127-1155 (1999).
17. J. N. Weiss, P. Korge, H. M. Honda, P. Ping, Role of the mitochondrial permeability transition in myocardial disease, Circ. Res. , 93, 292-301 (2003).
18. A. P. Halestrap, S. J. Clarke, S. A. Javadov, Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection, Cardiovasc. Res. , 61, 372-385 (2004).
19. F. Di Lisa, P. Bernardi, Mitochondria and ischemia-reperfusion injury of the heart: Fixing a hole, Cardiovasc. Res. , 70, 191-199 (2006).
20. W. Droge, Free radicals in the physiological control of cell function, Physiol Rev. , 82, 47-95 (2002).
21. J. F. Turrens, Mitochondrial formation of reactive oxygen species, J. Physiol. , 552, 335-344 (2003).
22. R. S. Balaban, S. Nemoto, T. Finkel, Mitochondria, oxidants, aging, Cell, 120, 483-495 (2005).
23. J. St-Pierre, J. A. Buckingham, S. J. Roebuck, M. D. Brand, Topology of superoxide production from different sites in the mitochondrial electron transport chain, J. Biol. Chem. , 277, 44784-44790 (2002).
24. I. Fridovich, Mitochondria: are they the seat of senescence?, Aging Cell, 3, 13-16 (2004).
25. I. Fridovich, Superoxide radical and superoxide dismutases, Annu. Rev. Biochem. , 64, 97-112 (1995).
26. L. Flohe, F. Ursini, Peroxidase: a term of many meanings, Antioxid. Redox. Signal. , 10, 1485-1490 (2008).
27. W. Zhao, G. C. Fan, Z. G. Zhang, et al. Protection of peroxiredoxin II on oxidative stressinduced cardiomyocyte death and apoptosis, Basic Res. Cardiol. , 104(4), 377-389 (2008).
28. F. J. Giordano, Oxygen, oxidative stress, hypoxia and heart failure, J. Clin. Invest, 115, 500-508 (2005).
29. J. J. Poderoso, M. C. Carreras, C. Lisdero, et al. Nitric oxide inhibits electron transfer and increases superoxide radical production in rat heart mitochondria and submitochondrial particles, Arch. Biochem. Biophys. , 328, 85-92 (1996).
30. T. M. Sarkela, J. Berthiaume, S. Elfering, et al. The modulation of oxygen radical production by nitric oxide in mitochondria, J. Biol. Chem. , 276, 6945-6949 (2001).
31. G. C. Brown, C. E. Cooper, Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase, FEBS Lett. , 356, 295-298 (1994).
32. M. W. Cleeter, J. M. Cooper, V. M. rley-Usmar, et al. Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases, FEBS Lett. , 345, 50-54 (1994).
33. B. Beltran, A. Mathur, M. R. Duchen, et al. The effect of nitric oxide on cell respiration: A key to understanding its role in cell survival or death, Proc. Natl. Acad. Sci. U. S. A, 97, 14602-14607 (2000).
34. V. Haynes, S. L. Elfering, R. J. Squires et al. Mitochondrial nitric-oxide synthase: role in pathophysiology, IUBMB. Life, 55, 599-603 (2003).
35. J. F. Turrens, Mitochondrial formation of reactive oxygen species, J. Physiol, 552, 335-344 (2003).
36. J. S. Beckman, W. H. Koppenol, Nitric oxide, superoxide, peroxynitrite: the good, the bad, ugly, Am. J. Physiol, 271, C1424-C1437 (1996).
37. M. Canton, I. Neverova, R. Menabò , et al. Evidence of myofibrillar protein oxidation induced by postischemic reperfusion in isolated rat hearts, Am. J. Physiol Heart Circ. Physiol, 286, H870-H877 (2004).
38. R. Bolli, E. Marban, Molecular and cellular mechanisms of myocardial stunning, Physiol. Rev. , 79, 609-634 (1999).
39. E. Murphy, C. Steenbergen, Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury, Physiol Rev. , 88, 581-609 (2008).
40. T. Ide, H. Tsutsui, S. Kinugawa, N. Suematsu, et al. Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium, Circ. Res. , 86, 152-157 (2000).
41. D. Cesselli, I. Jakoniuk, L. Barlucchi, et al. Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy, Circ. Res. , 89, 279-286 (2001).
42. M. Rota, N. Lecapitaine, T. Hosoda, et al. Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66shc gene, Circ. Res. , 99, 42-52 (2006).
43. S. M. Davidson, M. R. Duchen, Endothelial mitochondria: contributing to vascular function and disease, Circ. Res. , 100, 1128-1141 (2007).
44. N. R. Madamanchi, M. S. Runge, Mitochondrial dysfunction in atherosclerosis, Circ. Res. , 100, 460-473 (2007).
45. J. Gutierrez, S. W. Ballinger, V. M. Darley-Usmar, A. Landar, Free radicals, mitochondria, oxidized lipids: the emerging role in signal transduction in vascular cells, Circ. Res. , 99, 924-932 (2006).
46. R. Dworakowski, S. P. Alom-Ruiz, A. M. Shah, NADPH oxidase-derived reactive oxygen species in the regulation of endothelial phenotype, Pharmacol. Rep. , 60, 21-28 (2008).
47. J. Bauersachs, J. D. Widder, Endothelial dysfunction in heart failure, Pharmacol. Rep. , 60, 119-126 (2008).
48. M. Giorgio, M. Trinei, E. Migliaccio, P. G. Pelicci, Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals?, Nat. Rev. Mol. Cell Biol. , 8, 722-728 (2007).
49. Y. M. Janssen-Heininger, B. T. Mossman, N. H. Heintz, et al. Redox-based regulation of signal transduction: principles, pitfalls, promises, Free Radic. Biol. Med. , 45, 1-17 (2008).
50. W. Droge, Free radicals in the physiological control of cell function, Physiol Rev. , 82, 47-95 (2002).
51. F. Di Lisa, N. Kaludercic, A. Carpi, et al. Mitochondrial pathways for ROS formation and myocardial injury: the relevance of p66(Shc) and monoamine oxidase, Basic Res. Cardiol. , 104, 131-139 (2009).
52. J. C. Shih, K. Chen, M. J. Ridd, Monoamine oxidase: from genes to behavior, Annu. Rev. Neurosci. , 22, 197-217 (1999).
53. E. Cadenas, K. J. Davies, Mitochondrial free radical generation, oxidative stress, aging, Free Radic. Biol. Med. , 29, 222-230 (2000).
54. P. Bianchi, O. Kunduzova, E. Masini, et al. Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury, Circulation, 112, 3297-3305 (2005).
55. A. Carpi, R. Menabò , N. Kaludercic, et al. The cardioprotective effects elicited by p66(Shc) ablation demonstrate the crucial role of mitochondrial ROS formation in ischemia/reperfusion injury, Biochim. Biophys. Acta, 1787, 774-780 (2009).
56. M. Giorgio, E. Migliaccio, F. Orsini, et al. Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis, Cell, 122, 221-233 (2005).
57. M. Trinei, M. Giorgio, A. Cicalese, et al. A p53-p66Shc signalling pathway controls intracellular redox status, levels of oxidation-damaged DNA and oxidative stressinduced apoptosis, Oncogene, 21, 3872-3878 (2002).
58. F. Orsini, E. Migliaccio, M. Moroni, et al. The life span determinant p66Shc localizes to mitochondria where it associates with mitochondrial heat shock protein 70 and regulates trans-membrane potential, J. Biol. Chem. , 279, 25689-25695 (2004).
59. P. S. Brookes, Y. Yoon, J. L. Robotham, et al. Calcium, ATP, ROS: a mitochondrial love-hate triangle, Am. J. Physiol Cell Physiol, 287, C817-C833 (2004).
60. R. G. Hansford, Dehydrogenase activation by Ca2p in cells and tissues, J. Bioenerg. Biomembr. , 23, 823-854 (1991).
61. A. Jekabsone, L. Ivanoviene, G. C. Brown, V. Borutaite, Nitric oxide and calcium together inactivate mitochondrial complex I and induce cytochrome c release, J. Mol. Cell Cardiol. , 35, 803-809 (2003).
62. G. C. Brown, C. E. Cooper, Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase, FEBS Lett. , 356, 295-298 (1994).
63. S. Orrenius, B. Zhivotovsky, P. Nicotera, Regulation of cell death: the calciumapoptosis link, Nat. Rev. Mol. Cell Biol. , 4, 552-565 (2003).
64. M. Zoratti, I. Szabo, The mitochondrial permeability transition, Biochim. Biophys. Acta, 1241, 139-176 (1995).
65. M. Crompton, The mitochondrial permeability transition pore and its role in cell death, Biochem. J. , 341, 233-249 (1999).
66. V. Petronilli, D. Penzo, L. Scorrano, et al. The mitochondrial permeability transition, release of cytochrome c and cell death. Correlation with the duration of pore openings in situ, J. Biol. Chem. , 276, 12030-12034 (2001).
67. F. Di Lisa, P. Bernardi, A CaPful of mechanisms regulating the mitochondrial permeability transition, J. Mol. Cell Cardiol. , 46, 775-780 (2009).
68. J. S. Kim, Y. Jin, J. J. Lemasters, Reactive oxygen species, but not Ca2p overloading, trigger pH- and mitochondrial permeability transition-dependent death of adult rat myocytes after ischemia-reperfusion, Am. J. Physiol Heart Circ. Physiol, 290, H2024-H2034 (2006).
69. D. Penzo, V. Petronilli, A. Angelin, et al. Arachidonic acid released by phospholipase A(2) activation triggers Ca(2p)-dependent apoptosis through the mitochondrial pathway, J. Biol. Chem. , 279, 25219-25225 (2004).
70. D. E. Goll, V. F. Thompson, H. Li, W. Wei, J. Cong, The calpain system, Physiol Rev. , 83, 731-801 (2003).
71. N. Shulga, J. G. Pastorino, Acyl coenzyme A-binding protein augments bidinduced mitochondrial damage and cell death by activating mu-calpain, J. Biol. Chem. , 281, 30824-30833 (2006).
72. H. I. Aguilar, R. Botla, A. S. Arora, et al. Induction of the mitochondrial permeability transition by protease activity in rats: a mechanism of hepatocyte necrosis, Gastroenterology, 110, 558-566 (1996).
73. B. M. Polster, G. Basanez, A. Etxebarria, et al. Calpain I induces cleavage and release of apoptosis-inducing factor from isolated mitochondria, J. Biol. Chem. , 280, 6447-6454 (2005).
74. M. Chen, D. J. Won, S. Krajewski, R. A. Gottlieb, Calpain and mitochondria in ischemia/reperfusion injury, J. Biol. Chem. , 277, 29181-29186 (2002).
75. M. Degli Esposti, Inhibitors of NADH-ubiquinone reductase: an overview, Biochim. Biophys. Acta, 1364, 222-235 (1998).
76. R. R. Ramsay, J. I. Salach, J. Dadgar, T. P. Singer, Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism, Biochem. Biophys. Res. Commun. , 135, 269-275 (1986).
77. R. Banerjee, A. A. Starkov, M. F. Beal, B. Thomas, Mitochondrial dysfunction in the limelight of Parkinson,s disease pathogenesis, Biochim. Biophys. Acta, 1792, 651-663 (2009).
78. M. Damiano, L. Galvan, N. Deglon, E. Brouillet, Mitochondria in Huntington,s disease, Biochim. Biophys. Acta, 1802(1), 52-61 (2009).
79. F. Di Lisa, R. Menabò , M. Canton, et al. Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NADp and is a causative event in the death of myocytes in post-ischemic reperfusion of the heart, J. Biol. Chem. , 276, 2571-2575 (2001).
80. F. Di Lisa, M. Ziegler, Pathophysiological relevance of mitochondria in NADp metabolism, FEBS Lett. , 492, 4-8 (2001).
81. S. Bruzzone, G. Dodoni, N. Kaludercic, et al. Mitochondrial dysfunction induced by a cytotoxic adenine dinucleotide produced by ADP-ribosyl cyclases from cADPR, J. Biol. Chem. , 282, 5045-5052 (2007).
82. W. Irwin, E. Fontaine, L. Agnolucci, et al. Bupivacaine myotoxicity is mediated by mitochondria, J. Biol. Chem. , 277, 12221-12227 (2002).
83. K. Knudsen, S. M. Beckman, S. Blomberg, et al. Central nervous and cardiovascular effects of i. v. infusions of ropivacaine, bupivacaine and placebo in volunteers, Br. J. Anaesth. , 78, 507-514 (1997).
84. S. Papa, V. P. Skulachev, Reactive oxygen species, mitochondria, apoptosis and aging, Mol. Cell Biochem. , 174, 305-319 (1997).
85. F. Di Lisa, P. Bernardi, Mitochondrial function and myocardial aging. A critical analysis of the role of permeability transition, Cardiovasc. Res. , 66, 222-232 (2005).
86. P. Bernardi, L. Scorrano, R. Colonna, et al. Mitochondria and cell death. Mechanistic aspects and methodological issues, Eur. J. Biochem. , 264, 687-701 (1999).
87. J. M. Berthiaume, K. B. Wallace, Adriamycin-induced oxidative mitochondrial cardiotoxicity, Cell Biol. Toxicol. , 23, 15-25 (2007).
88. G. Minotti, P. Menna, E. Salvatorelli, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity, Pharmacol. Rev. , 56, 185-229 (2004).
89. P. Menna, E. Salvatorelli, G. Minotti, Cardiotoxicity of antitumor drugs, Chem. Res. Toxicol. , 21, 978-989 (2008).
90. K. J. Davies, J. H. Doroshow, Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase, J. Biol. Chem. , 261, 3060-3067 (1986).
91. J. H. Doroshow, K. J. Davies, Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, hydroxyl radical, J. Biol. Chem. , 261, 3068-3074 (1986).
92. P. J. Oliveira, M. S. Santos, K. B. Wallace, Doxorubicin-induced thiol-dependent alteration of cardiac mitochondrial permeability transition and respiration, Biochemistry (Moscow), 71, 194-199 (2006).
93. O. Speer, S. Morkunaite-Haimi, J. Liobikas, et al. Rapid suppression of mitochondrial permeability transition by methylglyoxal. Role of reversible arginine modification, J. Biol. Chem. , 278, 34757-34763 (2003).
94. K. B. Wallace, Doxorubicin-induced cardiac mitochondrionopathy, Pharmacol. Toxicol. , 93, 105-115 (2003).
95. K. B. Wallace, Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis, Cardiovasc. Toxicol. , 7, 101-107 (2007).
96. E. Goormaghtigh, P. Huart, M. Praet, et al. Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity, Biophys. Chem. , 35, 247-257 (1990).
97. K. Nicolay, J. J. Fok, W. Voorhout, et al. Cytofluorescence detection of adriamycinmitochondria interactions in isolated, perfused rat heart, Biochim. Biophys. Acta, 887, 35-41 (1986).
98. 2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure, J. Clin. Invest, 117, 2431-2444 (2007).
99. E. Basso, L. Fante, J. Fowlkes, et al. Properties of the permeability transition pore in mitochondria devoid of Cyclophilin D, J. Biol. Chem. , 280, 18558-18561 (2005).
100. C. P. Baines,R. A. Kaiser,N. H. Purcell, et al. Loss of cyclophilinDreveals a critical role for mitochondrial permeability transition in cell death, Nature, 434, 658-662 (2005).
101. D. C. Wallace, Mitochondrial defects in cardiomyopathy and neuromuscular disease, Am. Heart J. , 139, S70-S85 (2000).
102. M. J. Bennett, P. Rinaldo, A. W. Strauss, Inborn errors of mitochondrial fatty acid oxidation, Crit Rev. Clin. Lab Sci. , 37, 1-44 (2000).
103. J. A. Smeitink, M. Zeviani, D. M. Turnbull, H. T. Jacobs, Mitochondrial medicine: a metabolic perspective on the pathology of oxidative phosphorylation disorders, Cell Metab, 3, 9-13 (2006).
104. E. J. Lesnefsky, S. Moghaddas, B. Tandler, et al. Mitochondrial dysfunction in cardiac disease: ischemia-reperfusion, aging, heart failure, J. Mol. Cell Cardiol. , 33, 1065-1089 (2001).
105. D. S. Millington, T. P. Bohan, C. R. Roe, et al. Valproylcarnitine: a novel drug metabolite identified by fast atom bombardment and thermospray liquid chromatography- mass spectrometry, Clin. Chim. Acta, 145, 69-76 (1985).
106. B. Melegh, J. Kerner, L. L. Bieber, Pivampicillin-promoted excretion of pivaloylcarnitine in humans, Biochem. Pharmacol. , 36, 3405-3409 (1987).
107. E. P. Brass, Pivalate-generating prodrugs and carnitine homeostasis in man, Pharmacol. Rev. , 54, 589-598 (2002).
108. T. L. Broderick, Hypocarnitinaemia induced by sodium pivalate in the rat is associated with left ventricular dysfunction and impaired energy metabolism, Drugs R. D. , 7, 153-161 (2006).
109. R. G. Hansford, Relation between mitochondrial calcium transport and control of energy metabolism, Rev. Physiol. Biochem. Pharmacol. , 102, 1-72 (1985).
110. N. Siliprandi, L. Sartorelli, M. Ciman, F. Di Lisa, Carnitine: metabolism and clinical chemistry, Clin. Chim. Acta, 183, 3-11 (1989).
111. A. N. Andrieu, J. P. Jaffrezou, S. Hatem, et al. L-carnitine prevents doxorubicininduced apoptosis of cardiac myocytes: role of inhibition of ceramide generation, FASEB J. , 13, 1501-1510 (1999).
112. M. C. Mutomba, H. Yuan, M. Konyavko, et al. Regulation of the activity of caspases by L-carnitine and palmitoylcarnitine, Febs Lett. , 478, 19-25 (2000).
113. M. B. Paumen, Y. Ishida, M. Muramatsu, et al. Inhibition of carnitine palmitoyltransferase I augments sphingolipid synthesis and palmitate-induced apoptosis, J. Biol. Chem. , 272, 3324-3329 (1997).
114. G. Dodoni, M. Canton, V. Petronilli, et al. Induction of the mitochondrial permeability transition by the DNA alkylating agentN-methyl-N0-nitro-N-nitrosoguanidine. Sorting cause and consequence of mitochondrial dysfunction, Biochim. Biophys. Acta, 1658, 58-63 (2004).
115. G. Minotti, N. Sarvazyan, The anthracyclines: when good things go bad, Cardiovasc. Toxicol. , 7, 53-55 (2007).
116. D. M. Yellon, D. J. Hausenloy, Myocardial reperfusion injury, N. Engl. J. Med. , 357, 1121-1135 (2007).
117. T. Pain, X. M. Yang, S. D. Critz, et al. Opening of mitochondrial K(ATP) channels triggers the preconditioned state by generating free radicals, Circ. Res. , 87, 460-466 (2000).
118. R. Schulz, M. V. Cohen, M. Behrends, et al. Signal transduction of ischemic preconditioning, Cardiovasc. Res. , 52, 181-198 (2001).
119. A. D. Costa, R. Jakob, C. L. Costa, et al. The mechanism by which the mitochondrial ATP-sensitive Kp channel opening and H2O2 inhibit the mitochondrial permeability transition, J. Biol. Chem. , 281, 20801-20808 (2006).
120. D. F. Stowe, L. G. Kevin, Cardiac preconditioning by volatile anesthetic agents: a defining role for altered mitochondrial bioenergetics, Antioxid. Redox. Signal. , 6, 439-448 (2004).
121. A. Stadnicka, J. Marinovic, M. Ljubkovic, et al. Volatile anesthetic-induced cardiac preconditioning, J. Anesth. , 21, 212-219 (2007).